By leveraging our proprietary portfolio including: iPSC-derived immune cell therapies including iNK cells, iαβT-cells, iγδT cells and iMACs Next-generation Immune Cell Engagers (ICEs) such as Mytomab (ADCC enhancer/
NK cell engager) Evotec is able to design rational and synergistic oncology strategies. This unique combination addresses cancer resistance mechanisms by uniting the adaptability of engineered iPSC-derived immune cells with the precision and modularity of ICEs.
